Patent: 10,231,981
✉ Email this page to a colleague
Summary for Patent: 10,231,981
Title: | Subcutaneously administered anti-IL-6 receptor antibody for treatment of juvenile idiopathic arthritis |
Abstract: | The present application discloses methods for treating an IL-6-mediated disorder such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), systemic JIA (sJIA), polyarticular course JIA (pcJIA), systemic sclerosis, or giant cell arteritis (GCA), with subcutaneously administered antibody that binds interleukin-6 receptor (anti-IL-6R antibody). In particular, it relates to identification of a fixed dose of anti-IL-6R antibody, e.g. tocilizumab, which is safe and effective for subcutaneous administration in patients with IL-6-mediated disorders. In addition, formulations and devices useful for subcutaneous administration of an anti-IL-6R antibody are disclosed. |
Inventor(s): | Zhang; Xiaoping (Wayne, NJ), Terao; Kimio (Funabashi, JP), Harari; Olivier Alfred (London, GB) |
Assignee: | Chugai Seiyaku Kabushiki Kaisha (Tokyo, JP) Hoffmann-La Roche Inc. (Little Falls, NJ) |
Application Number: | 15/668,445 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 10,231,981 |
Patent Claims: | see list of patent claims |
Details for Patent 10,231,981
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | ACTEMRA | tocilizumab | Injection | 125276 | 01/08/2010 | ⤷ Try a Trial | 2030-11-08 |
Genentech, Inc. | ACTEMRA | tocilizumab | Injection | 125472 | 10/21/2013 | ⤷ Try a Trial | 2030-11-08 |
Genentech, Inc. | ACTEMRA | tocilizumab | Injection | 125472 | 11/19/2018 | ⤷ Try a Trial | 2030-11-08 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |